Neumora Therapeutics (NMRA) IPO Misrepresentation Case
$NMRA investors filed a lawsuit against Neumora Therapeutics, alleging the company misled shareholders about the effectiveness of its lead drug, Navacaprant, and the risks associated with its clinical trials.
On January 2, 2025, Neumora revealed that its Phase 3 KOASTAL-1 study failed to show significant improvements over a placebo. Following this, $NMRA dropped 88.7%.
$NMRA investors can join this case to be notified about potential recovery.
Between September 15, 2023, and January 2, 2025, Neumora conducted its IPO, raising over $250 million, and assured investors that Navacaprant, its leading drug candidate for major depressive disorder (MDD), had strong Phase 2 trial results and high prospects for Phase 3 success.
The company claimed that the Phase 2 trial showed positive response rates and positioned Navacaprant as a breakthrough treatment. However, Neumora failed to disclose key risks, including changes in trial criteria, small patient sample sizes, and demographic imbalances, which made the Phase 2 data unreliable for predicting Phase 3 results.
On January 2, 2025, Neumora announced that KOASTAL-1 failed to meet both its primary and secondary endpoints, showing no significant improvement over a placebo. The company admitted that results varied dramatically based on patient gender, an issue that was not disclosed before the IPO.
Following this news, $NMRA collapsed 88.7%, wiping out nearly all of its post-IPO value.
Based on these events, $NMRA investors filed a lawsuit against Neumora Therapeutics, claiming the company:
It misled investors about the reliability of its Phase 2 trial results and the likelihood of Phase 3 success.
It failed to disclose critical risks, including data limitations and demographic imbalances, that made its projections unreliable.
Investors believe Neumora misrepresented the strength of Navacaprant’s clinical trials.